STAA is trading above every analyst's published price target — a sign that the stock has moved faster than Wall Street's models anticipated, and that the heavy short interest has not been enough to hold it back.
The most striking element of the STAAR story right now is the positioning of Broadwood Capital, the Connecticut-based fund that holds a third of the company. In mid-March, Broadwood added roughly 615,000 shares across two days — paying around $18.6 a piece, a total commitment of just over $11 million. With STAAR closing Tuesday at $28.18, that bloc has gained more than 50% in less than two months. The 90-day net insider and related-entity buying sits at roughly 684,000 shares and $12.6 million in value — one of the more consequential accumulation episodes in recent quarters for a stock this size.
Short interest remains heavy, but something broke this week. At 14.4% of free float, STAAR still carries a meaningful short base — and its ORTEX short score of 69.3 places it in elevated territory. But the pace of covering has been notable: estimated short interest dropped nearly 13% week-on-week, falling from roughly 8.47 million shares to 7.17 million. That's the sharpest single-week unwind in the past 30-day window, even as the one-month trend remains up 11.6%. The borrow market tells a relaxed story alongside that — cost to borrow is running at just 0.53%, barely changed on the month, and availability is not constrained. With two-thirds of the lending pool still unused, there is no mechanical pressure on short-sellers to cover. The week's covering looks voluntary, not forced.
Options positioning adds a small but consistent signal. The put/call ratio has eased to 0.47, just below its 20-day average of 0.50. The z-score of -0.73 is not dramatic — this is a mild call skew, not a conviction trade. But it fits the price action: options traders have been leaning toward calls as the stock climbed, and the step-down in the PCR from the 0.58–0.61 readings seen in early April aligns with the period when the stock started recovering.
The Street, however, has not kept pace. The consensus is a Hold, with nine analysts parked there against just two Buys. The mean price target of around $21 is now nearly $7 below the current price — an unusual situation where the stock has simply outrun the models. The most recent moves, both from early April, were in the right direction: Canaccord Genuity upgraded to Buy with a $27 target, and Wedbush lifted to $26 while staying Neutral. Both of those targets are now underwater relative to where the stock trades today. Earlier in the year, Wells Fargo slashed its target nearly in half — from $30.75 to $16 — and Stifel trimmed twice. The bull case centres on a China recovery and margin improvements from restructuring; the bear case flags competition in the Chinese implantable lens market and the risks from recent leadership changes. Factor scores are mixed: 90-day EPS momentum ranks in the 93rd percentile — a strong estimate revision trend — but the 30-day EPS momentum score is near the bottom at the 13th percentile, suggesting the near-term estimate picture has cooled.
Ownership concentration is unusually high. Broadwood holds 32.6% of shares, Yunqi Capital 6.6% — adding 750,000 shares in Q1 — and the float available to trade is correspondingly narrow. That structure matters when short interest is running at 14% of float: with this much stock locked up by a few concentrated holders, any dislocation between supply and demand in the borrow market can amplify quickly, even if current cost-to-borrow conditions show no stress.
The next earnings event is scheduled for June 18. Q1 results appear to have crossed the wire around the time of writing — the prior earnings date in the history carries a muted reaction of under 1% on the day, though the five-day follow-through was negative at nearly -9.6%. How the market digests any forward commentary on China revenue recovery and restructuring progress will be the read-through to watch ahead of that June date.
See the live data behind this article on ORTEX.
Open STAA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
